Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Non-cash Items (2019 - 2025)

Historic Non-cash Items for Kymera Therapeutics (KYMR) over the last 7 years, with Q3 2025 value amounting to $250.1 million.

  • Kymera Therapeutics' Non-cash Items rose 6761.85% to $250.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $250.1 million, marking a year-over-year increase of 6761.85%. This contributed to the annual value of $97.7 million for FY2024, which is 9691.87% up from last year.
  • According to the latest figures from Q3 2025, Kymera Therapeutics' Non-cash Items is $250.1 million, which was up 6761.85% from $134.2 million recorded in Q2 2025.
  • In the past 5 years, Kymera Therapeutics' Non-cash Items ranged from a high of $250.1 million in Q3 2025 and a low of $1.6 million during Q1 2021
  • In the last 5 years, Kymera Therapeutics' Non-cash Items had a median value of $82.5 million in 2023 and averaged $92.8 million.
  • Its Non-cash Items has fluctuated over the past 5 years, first plummeted by 9880.03% in 2021, then surged by 837447.47% in 2022.
  • Quarter analysis of 5 years shows Kymera Therapeutics' Non-cash Items stood at $246.9 million in 2021, then crashed by 77.35% to $55.9 million in 2022, then decreased by 11.28% to $49.6 million in 2023, then surged by 96.92% to $97.7 million in 2024, then surged by 155.9% to $250.1 million in 2025.
  • Its Non-cash Items stands at $250.1 million for Q3 2025, versus $134.2 million for Q2 2025 and $6.6 million for Q1 2025.